Nymox Announces Private Placements of $3 Million

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce recent completion of private placements with proceeds totaling US $3.0 million. There were no warrants or fees associated with the transactions. The placements were with long-term shareholders of the Company, and will be used for general corporate purposes.

Nymox announced previously that the Company has filed for approval in Europe for its new drug Fexapotide Triflutate for the treatment of BPH (prostate enlargement). The Company has also reported that there will be subsequent filings in other jurisdictions for Fexapotide. Nymox has previously announced that there will be increased new communication activities with the medical and financial communities, and significant initiatives for business collaborations to promote the advancement of marketing of Fexapotide for the treatment of BPH.

The Company announced on August 7 that an important large symposium and panel discussion of the Company's new drug Fexapotide Triflutate will be held at the September meeting of the American Urological Association, Mid-Atlantic Section. The September symposium at the AUA meeting will feature presentations from prominent Fexapotide Clinical Trial urologists, and will include panel discussions of data and results from the U.S. Fexapotide trials undertaken in 2009-2017. The Chairperson of the Symposium will be Ronald Tutrone MD, FACS of Chesapeake Urology, Towson, MD.

Fexapotide has been in development by Nymox for over 10 years. Clinical trials have shown long-term symptomatic improvement, long-term reduction in the need for BPH surgery, long-term reduced prostate cancer risk, and an excellent long-term safety profile with no sexual side effects in comparison to available drug treatments. Fexapotide Triflutate is administered at an office visit and consists of a single painless injection that takes a few minutes or less, with no requirements of anesthesia, or analgesia or catheterization. There are none of the typical sexual and other distressing side effects seen with conventional BPH treatments. BPH is highly prevalent in middle aged and elderly men, affecting millions of men world-wide. Existing medical treatments for BPH generally provide temporary relief only, and are commonly discontinued by patients due to side effects and little efficacy. Surgical treatments are effective but often have permanent retrograde ejaculation as a result, and other problems and risks are associated.

For more information please contact [e-mail] or 800-936-9669.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2016, and its Quarterly Reports.

Contact:
Paul Averback
Nymox Pharmaceutical Corporation
800-93NYMOX
www.nymox.com